Your browser doesn't support javascript.
loading
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan, Jun; Darb-Esfahani, Silvia; Richter, Rolf; Taube, Eliane T; Ruscito, Ilary; Mahner, Sven; Woelber, Linn; Prieske, Katharina; Concin, Nicole; Vergote, Ignace; Van Nieuwenhuysen, Els; Achimas-Cadariu, Patriciu; Glajzer, Joanna; Woopen, Hannah; Stanske, Mandy; Kulbe, Hagen; Denkert, Carsten; Sehouli, Jalid; Braicu, Elena Ioana.
Afiliación
  • Guan J; Department of Gynecology, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Darb-Esfahani S; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Richter R; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Taube ET; Berlin Institute of Health, Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Ruscito I; Department of Gynecology, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Mahner S; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Woelber L; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Prieske K; Berlin Institute of Health, Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Concin N; Department of Gynecology, Berlin Institute of Health, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Vergote I; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Van Nieuwenhuysen E; Laboratory of Cell Therapy and Tumor Immunology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Achimas-Cadariu P; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Glajzer J; Department of Gynecology, University-Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
  • Woopen H; Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Stanske M; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Kulbe H; Department of Gynecology, University-Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
  • Denkert C; Tumorbank Ovarian Cancer Network, Berlin, Germany.
  • Sehouli J; Department of Gynecology, University-Medical-Center Hamburg-Eppendorf, Hamburg, Germany.
  • Braicu EI; Tumorbank Ovarian Cancer Network, Berlin, Germany.
J Cancer Res Clin Oncol ; 145(4): 1063-1073, 2019 Apr.
Article en En | MEDLINE | ID: mdl-30810838
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Receptor 2 de Factores de Crecimiento Endotelial Vascular Límite: Female / Humans / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Receptor 2 de Factores de Crecimiento Endotelial Vascular Límite: Female / Humans / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Año: 2019 Tipo del documento: Article País de afiliación: Alemania